PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...

The waiting time for Latin American patients with cancer, central nervous system disorders or rare diseases can take up to ...

Olverembatinib, developed by Ascentage Pharma, will be added to China’s National Reimbursement Drug List (NRDL) starting next ...

A report from DelveInsight highlights over 20 companies developing 22 treatments for myotonic dystrophy, with progress in ...

The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa ...

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for ...

Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of ...

The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of ...

UK-based drugmaker Advanz Pharma has announced that following the grant of a temporary suspension, as announced on last month ...

The US Food and Drug Administration (FDA) yesterday announced its Fiscal Year 2025 Generic Drug User Fee Amendments (GDUFA).

Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...

Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex ...